Investments, Debt and Equity Securities [Abstract] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Corporate bonds [Member] Corporate Bond Securities [Member] US Treasury and Government [Member] US Treasury and Government [Member] Commercial paper [Member] Commercial Paper [Member] Schedule of Available-for-sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Unrealized loss position, fair value, less than 12 months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Gross unrealized losses, less than 12 months Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss Unrealized loss position, fair value,12 months or greater Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value Gross unrealized losses, 12 months or greater Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Aggregate Loss Unrealized loss position, fair value Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value Gross unrealized losses Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Options [Member] Employee Stock Option [Member] ESPP [Member] Employee Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Weighted average grant-date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] Global [Member] Global [Member] Global [Member] Japan [Member] JAPAN Royalty Tier [Axis] royalty tier [Axis] royalty tier [Axis] royalty tier [Domain] royalty tier [Domain] [Domain] for royalty tier [Axis] Initial [Member] Initial [Member] Initial [Member] Final tier [Member] Final Tier [Member] Final Tier[Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Collaborative arrangement with Takeda [Member] Collaborative Arrangement with Takeda [Member] Collaborative Arrangement with Takeda [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Upfront and milestone payments Upfront and milestone payments Upfront and milestone payments. Deferred revenue, recognition period Deferred Revenue, Recognition Period Deferred Revenue, Recognition Period Maximum amount eligible for development and regulatory milestones Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones Maximum amount eligible for development and regulatory milestones under collaborations agreement. Maximum amount eligible for commercial milestones under collaborations agreement Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement Maximum amount eligible for commercial milestones under collaborations agreement. Percent of royalty on net sale Percent of royalty on net sale Percent of royalty on net sale. Royalty tier Royalty Tier Royalty Tier Research and development arrangement performed for others, reimbursement for costs incurred, percent Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent Collaboration period to achieve specified levels of commercial performance Collaborative Arrangement, Achievement Levels of Commercial Performance, Period Collaborative Arrangement, Achievement Levels of Commercial Performance, Period Collaboration revenues Contracts Revenue Current portion of deferred revenue Deferred Revenue, Current Long-term portion of deferred revenue Deferred Revenue, Noncurrent Period for specific commercial performance Period Of Specific Sales Volume, Threshold Period Of Specific Sales Volume, Threshold Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization Stock-based compensation Share-based Compensation Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt Amortization of debt discounts and debt issuance costs Amortization of Debt Issuance Costs and Discounts Interest paid in kind Paid-in-Kind Interest Gain on other equity investments Gain (Loss) on Sale of Other Investments Changes in warrant fair value Fair Value Adjustment of Warrants Other Other Noncash Income (Expense) Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Trade and other receivables Increase (Decrease) in Accounts and Other Receivables Inventory, net Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other long-term assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation and benefits Increase (Decrease) in Employee Related Liabilities Accrued clinical trial liabilities Increase (Decrease) Accrued Clinical Liabilities Increase (decrease) accrued clinical liabilities Accrued collaboration liabilities Increase (Decrease) in Accrued Collaboration Liability Increase (Decrease) in Accrued Collaboration Liability Deferred revenue Increase (Decrease) in Deferred Revenue Other current and long-term liabilities Increase (Decrease) in Other Operating Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Purchases of investments Payments to Acquire Available-for-sale Securities, Debt Proceeds from maturities of investments Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Proceeds from sale of investments Proceeds from Sale of Available-for-sale Securities Purchase of restricted cash and investments Payments to Acquire Restricted Investments Proceeds from maturities of restricted cash and investments Increase (Decrease) in Restricted Cash and Investments Proceeds from other equity investments Proceeds from Sale and Maturity of Other Investments Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Principal repayments of debt Repayments of Long-term Debt Payments on conversion of convertible notes Payments for Conversion of Convertible Debt Payments for Conversion of Convertible Debt Proceeds from issuance of common stock, net Proceeds from Issuance of Common Stock Proceeds from exercise of stock options Proceeds from Stock Options Exercised Proceeds from employee stock purchase plan Proceeds from Stock Plans Taxes paid related to net share settlement of equity awards Payments Related to Tax Withholding for Share-based Compensation Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of year Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of year Supplemental cash flow disclosure: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Cash paid for taxes Income Taxes Paid Non-cash investing and financing activity: Noncash Investing and Financing Items [Abstract] Construction in progress deemed to have been acquired under build-to-suit lease CIP deemed acquired in Build-to-Suit Lease CIP deemed acquired in Build-to-Suit Lease Issuance of common stock in settlement of convertible notes Conversion of Stock, Amount Issued Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Segment Reporting [Abstract] Schedule of Net Product Revenue by Product Revenue from External Customers by Products and Services [Table Text Block] Schedules of Revenue Concentration Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Revenue Earned from Geographic Region Revenue from External Customers by Geographic Areas [Table Text Block] Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Options outstanding at beginning of the year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Options outstanding at ending of the year (in shares) Exercisable at December 31, 2017 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Options outstanding at beginning of the year (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Options outstanding at ending of the year (in dollars per share) Exercisable at December 31, 2017 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Remaining Contractual Term, Options outstanding at December 31, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Exercisable at December 31, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate Intrinsic Value, Options outstanding at December 31, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate Intrinsic Value, Exercisable at December 31, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Property, Plant and Equipment [Abstract] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Income Tax Disclosure [Abstract] Current: Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Total current tax expense Current Income Tax Expense (Benefit) Deferred: Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Total deferred tax expense Deferred Income Tax Expense (Benefit) Provision for income taxes Income Tax Expense (Benefit) Commitments and Contingencies Disclosure [Abstract] Gross rental expense Operating Leases, Rent Expense less: Sublease income Operating Leases, Rent Expense, Sublease Rentals Net rental expense Operating Leases, Rent Expense, Net Document And Entity Information [Abstract] Document And Entity Information Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Entity Filer Category Entity Filer Category Current Fiscal Year End Date Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Public Float Entity Public Float Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Segment Information Segment Reporting Disclosure [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Computer equipment and software [Member] Computer Equipment And Software [Member] Computer Equipment And Software [Member]. Lab equipment [Member] Laboratory Equipment [Member] Laboratory Equipment [Member] Leasehold improvements [Member] Leasehold Improvements [Member] Furniture and fixtures [Member] Furniture and Fixtures [Member] Construction-in-progress [Member] Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Additional Paid-in Capital [Member] Accumulated Other Comprehensive (Loss) Income [Member] AOCI Attributable to Parent [Member] Accumulated Deficit [Member] Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance at beginning of period (in shares) Common Stock, Shares, Outstanding Balance at beginning of period Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Adoption of Accounting Standards Update No. 2016-09 Cumulative Effect of New Accounting Principle in Period of Adoption Other comprehensive (loss) income Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax Sale of shares of common stock, net (in shares) Stock Issued During Period, Shares, New Issues Sale of shares of common stock, net Stock Issued During Period, Value, New Issues Issuance of common stock in settlement of convertible notes (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Issuance of common stock in settlement of convertible notes Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of common stock under equity incentive and stock purchase plans (in shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Issuance of common stock under equity incentive and stock purchase plans Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures Issuance of common stock on warrant exercise (in shares) Stock Issued During Period, Shares, Other Issuance of common stock on warrant exercise Stock Issued During Period, Value, Other Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Warrants transferred from other long-term liabilities Adjustments to Additional Paid in Capital, Warrant Issued Balance at end of period (in shares) Balance at end of period Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Research and development expense [Member] Research and Development Expense [Member] Selling, general and administrative expense [Member] Selling, General and Administrative Expenses [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Total stock-based compensation Allocated Share-based Compensation Expense Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Interest Payment Type [Axis] Interest Payment Type [Axis] Interest Payment Type [Axis] Interest Payment Type [Domain] Interest Payment Type [Domain] [Domain] for Interest Payment Type [Axis] Coupon interest [Member] Coupon Interest [Member] Coupon Interest [Member] Payment-in-kind interest [Member] Payment-in-Kind Interest [Member] Payment-in-Kind Interest [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible notes [Member] Convertible Debt [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Secured Convertible Notes due June 2018 [Member] Secured Convertible Notes Due June 2018 [Member] Secured Convertible Notes Due June 2018 [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Repayment of principal Extinguishment of Debt, Including Paid in Kind Interest Extinguishment of Debt, Including Paid in Kind Interest Extinguishment of debt amount Extinguishment of Debt, Amount Interest paid in kind Prepayment penalty Debt Instrument, Prepayment Penalty Debt Instrument, Prepayment Penalty Accrued and unpaid interest Loss on extinguishment of debt Stated interest after extension option election Debt Instrument, Interest Rate, Stated Percentage after Extension Option Election Debt Instrument, Interest Rate, Stated Percentage after Extension Option Election Term loans payable [Member] Secured Debt [Member] Total debt Long-term Debt Balance of unamortized closing fees and expenses Debt Instruments, Unamortized Closing Fees And Expenses Debt instruments, unamortized closing fees and expenses. Quarterly Financial Information Disclosure [Abstract] Schedule of Quarterly Financial Data Quarterly Financial Information [Table Text Block] Inventory Disclosure [Abstract] Inventory, Current [Table] Inventory, Current [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Inventory [Member] Inventories [Member] Other long-term assets [Member] Other Long-term Assets [Member] Other Long-term Assets [Member] Inventory [Line Items] Inventory [Line Items] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Total Inventory, Gross Inventory write-down Inventory Write-down Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Collaborative Arrangement with Genentech [Member] Collaborative Arrangement with Genentech [Member] Collaborative Arrangement with Genentech [Member] Deferred Revenue Arrangement [Line Items] Deferred Revenue Arrangement [Line Items] Accrued clinical trial liabilities Accrued Clinical Liabilities, Current Accrued Clinical Liabilities, Current Recovery of net losses Recovery of Direct Costs Recovery of net losses, recognized in current fiscal year Recovery Of Expenses, Expenses In Current Fiscal Year Recovery Of Expenses, Expenses In Current Fiscal Year Schedule of Capital Leased Assets [Table] Schedule of Capital Leased Assets [Table] Operating lease and other financing lease [Member] Operating Lease and Other Financing Lease [Member] Operating Lease and Other Financing Lease [Member] Capital Leased Assets [Line Items] Capital Leased Assets [Line Items] Operating leases Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2018 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2019 Operating Leases, Future Minimum Payments, Due in Two Years 2020 Operating Leases, Future Minimum Payments, Due in Three Years 2021 Operating Leases, Future Minimum Payments, Due in Four Years 2022 Operating Leases, Future Minimum Payments, Due in Five Years Thereafter Operating Leases, Future Minimum Payments, Due Thereafter Future minimum lease payments, operating leases Operating Leases, Future Minimum Payments Due Other financing obligations Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2018 Capital Leases, Future Minimum Payments Due, Next Twelve Months 2019 Capital Leases, Future Minimum Payments Due in Two Years 2020 Capital Leases, Future Minimum Payments Due in Three Years 2021 Capital Leases, Future Minimum Payments Due in Four Years 2022 Capital Leases, Future Minimum Payments Due in Five Years Thereafter Capital Leases, Future Minimum Payments Due Thereafter Future minimum lease payments, capital leases Capital Leases, Future Minimum Payments Due Warrants and Rights Note Disclosure [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Senior subordinated notes [Member] Senior Subordinated Notes [Member] 2019 Notes [Member] Convertible Senior Subordinated Notes due August 15, 2019, 4.25% [Member] Convertible Senior Subordinated Notes due 2019, 4.25% [Member] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Over-allotment option [Member] Over-Allotment Option [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] 2014 Warrants [Member] Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member] Warrants Issued On January Twenty Second Two Thousand And Fourteen [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Number of shares issued pursuant to conversion (in shares) Debt Conversion, Converted Instrument, Shares Issued Aggregate principal amount of debt converted Debt Conversion, Converted Instrument, Amount Increase to shareholder's equity Public offering of common stock (in shares) Share price (in dollars per share) Share Price Net proceeds from public offering Warrant period Class of Warrant or Right, Period Class of Warrant or Right, Period Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Exercise price per share (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Fair Value of warrants Warrants and Rights Outstanding Shares withheld for exercise of warrants (in shares) Shares Withheld for Conversion of Warrants Shares Withheld for Conversion of Warrants Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Geographic concentration risk [Member] Geographic Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales revenue, net [Member] Sales Revenue, Goods, Net [Member] U.S. [Member] UNITED STATES Europe [Member] Europe [Member] Rest of the world [Member] Rest of World [Member] Rest of World [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues Revenues Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Beginning balance Unrecognized Tax Benefits Change relating to prior year provision Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions Unrecognized Tax Benefits, Increase (Decrease) Resulting from Prior Period Tax Positions Change relating to current year provision Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Reductions based on the lapse of the applicable statutes of limitations Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations Ending balance Number of operating segments Number of Operating Segments Gain (loss) on foreign exchange Foreign Currency Transaction Gain (Loss), before Tax Cash inducements Payments for Inducements of Debt Conversion Payments for Inducements of Debt Conversion Waiver of requirement to repay interest, described above Induced Conversion of Convertible Debt Expense, Interest Repayment Forgiveness Induced Conversion of Convertible Debt Expense, Interest Repayment Forgiveness Difference between the total settlement consideration attributed to the liability component of the 2019 Notes and the net carrying value of the liability Extinguishment of Debt, Difference Between Settlement Consideration and Net Carrying Value Extinguishment of Debt, Difference Between Settlement Consideration and Net Carrying Value Unamortized discount on redeemed notes Extinguishment of Debt, Write-off of Unamortized Debt Discounts Extinguishment of Debt, Write-off of Unamortized Debt Discounts Third-party costs Loss on Extinguishment of Debt, Transaction Costs Loss on Extinguishment of Debt, Transaction Costs Estimated Useful Lives of Property and Equipment Estimated Useful Lives Of Property Plant And Equipment [Table Text Block] Estimated Useful Lives Of Property Plant And Equipment [Table Text Block] Reserve Balances for Discounts and Allowances Revenue Recognition, Allowances [Policy Text Block] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Restatement adjustment [Member] Restatement Adjustment [Member] Collaborative arrangement with Ipsen [Member] Collaborative Arrangement with Ipsen [Member] Collaborative Arrangement with Ipsen [Member] Collaborative arrangement with Ipsen, approval of product by EC in Second-Line RCC [Member] Collaborative Arrangement with Ipsen, Approval of Cabozantinib by EC in Second-Line RCC [Member] Collaborative Arrangement with Ipsen, Approval of Product by EC in Second-Line RCC [Member] Products and Services [Axis] Products and Services [Axis] Products and Services [Domain] Products and Services [Domain] Cabometyx [Member] Cabometyx [Member] Cabometyx [Member] MilestoneObjective [Axis] MilestoneObjective [Axis] MilestoneObjective [Axis] MilestoneObjective [Domain] MilestoneObjective [Domain] [Domain] for MilestoneObjective [Axis] HCC Filing [Member] HCC Filing [Member] HCC Filing [Member] HCC Acceptance [Member] HCC Acceptance [Member] HCC Acceptance [Member] Second [Member] Second [Member] Second [Member] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] GlaxoSmithKline [Member] Glaxo Smith Kline [Member] Glaxo Smith Kline [Member]. Revenue recognized, milestones Revenue Recognition, Milestone Method, Revenue Recognized Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement Upfront payment reclassified Deferred Revenue Accrued collaboration liabilities Other Liabilities, Noncurrent Payment of reimbursements from collaboration arrangement Payment Of Reimbursements From Collaboration Arrangement Payment Of Reimbursements From Collaboration Arrangement Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Earnings Per Share [Abstract] Schedule of Reconciliation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Potential Shares of Common Stock Not Included In Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Money market funds [Member] Money Market Funds [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total financial assets Assets, Fair Value Disclosure, Recurring Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Deerfield Notes [Member] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Outstanding stock options, unvested RSUs and ESPP contributions [Member] Stock Compensation Plan [Member] Convertible debt [Member] Convertible Debt Securities [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total potentially dilutive shares Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Numerator: Earnings Per Share Reconciliation [Abstract] Net loss Net income allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Net income allocable to common stock for basic net income (loss) per share Net Income (Loss) Available to Common Stockholders, Basic Adjustment to net income allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted Net income allocable to common stock for diluted net income (loss) per share Net Income (Loss) Available to Common Stockholders, Diluted Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Weighted-average shares of common stock outstanding used in computing basic net income (loss) per share (in shares) Weighted Average Number of Shares Outstanding, Basic Outstanding stock options, unvested RSUs and ESPP contributions (in shares) Weighted Average Number Diluted Shares Outstanding Adjustment Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income (loss) per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Net income (loss) per share, basic (in dollars per share) Earnings Per Share, Basic Net income (loss) per share, diluted (in dollars per share) Earnings Per Share, Diluted Organization and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Schedule of Consolidated Net Income (Loss) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Reconciliation of Income Taxes At The Statutory Federal Income Tax Rate to Net Income Taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Schedule of Deferred Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Alameda, California [Member] Alameda, California [Member] Alameda, California [Member] South San Francisco, California [Member] South San Francisco, California [Member] South San Francisco, California [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Standby letters of credit [Member] Standby Letters of Credit [Member] Building shells [Member] Building Shells [Member] Building Shells [Member] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Optional amendment agreement [Member] Optional Amendment Agreement [Member] Optional Amendment Agreement [Member] Leasing Arrangement [Member] Operating Lease [Member] Operating Lease [Member] Building lease [Member] Standby Letter Of Credit Related To Building Lease [Member] Standby Letter Of Credit Related To Building Lease [Member] Workers Compensation Insurance Policy [Member] Standby Letter Of Credit Related To Workers Compensation Insurance Policy [Member] Standby Letter Of Credit Related To Workers Compensation Insurance Policy [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Area of leased property (in sqft) Area of Real Estate Property Term of lease contract Lessee Leasing Arrangements, Capital and Operating Leases, Term of Contract Lessee Leasing Arrangements, Capital and Operating Leases, Term of Contract Number of renewal options Capital and Operating Leases, Number of Renewal Options Capital and Operating Leases, Number of Renewal Options Renewal option term Lessee Leasing Arrangements, Capital and Operating Leases, Renewal Term Lessee Leasing Arrangements, Capital and Operating Leases, Renewal Term Number of options to terminate Capital and Operating Leases, Number of Options to Terminate Capital and Operating Leases, Number of Options to Terminate Option for additional area of lease (sq ft) Capital and Operating Leases, Option, Additional Area of Real Estate Property Capital and Operating Leases, Option, Additional Area of Real Estate Property Number of properties Number of Real Estate Properties Reimbursement cost for contract termination Loss Contingency, Estimate of Possible Loss Accrual for contract termination Loss Contingency Accrual, Provision Rent payable Loss Contingency Accrual Capital and operating leases, Minimum lease payments due Lessee Leasing Arrangements, Capital and Operating Leases, Minimum Lease Payments Due Lessee Leasing Arrangements, Capital and Operating Leases, Minimum Lease Payments Due Line of credit borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Number of letters of credit entered into (in debt instruments) Debt Instrument, Number of Instruments Debt Instrument, Number of Instruments Letters of credit outstanding Letters of Credit Outstanding, Amount Collateral provided for purchasing card program Collateral Provided For Purchasing Card Program Collateral Provided For Purchasing Card Program Net Income (Loss) Per Share Earnings Per Share [Text Block] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Fair value inputs, discount rate Fair Value Inputs, Discount Rate Genentech [Member] Profit Sharing Tiers [Axis] Profit Sharing Tiers [Axis] Profit Sharing Tiers [Axis] Profit Sharing Tiers [Domain] Profit Sharing Tiers [Domain] [Domain] for Profit Sharing Tiers [Axis] Profit Sharing Tier One [Member] Profit Sharing Tier One [Member] Profit Sharing Tier One [Member] Profit Sharing Tier Two [Member] Profit Sharing Tier Two [Member] Profit Sharing Tier Two [Member] Profit Sharing Tier Three [Member] Profit Sharing Tier Three [Member] Profit Sharing Tier Three [Member] Contract revenue [Member] Contract Revenue [Member] Contract Revenue [Member] Percentage of share of the Company in promotions Profit Sharing Agreement, Optional Percent of Total Sales Force Profit Sharing Agreement, Optional Percent of Total Sales Force Percent of profits Profit Sharing Agreement, Percent of Profits Profit Sharing Agreement, Percent of Profits Profit threshold Profit Sharing Agreement, Profit Threshold Profit Sharing Agreement, Profit Threshold Recovery (loss) of expenses, expenses prior to current fiscal year Recovery of Expenses, Expenses Prior to Current Fiscal Year Recovery of Expenses, Expenses Prior to Current Fiscal Year Schedule of Collaborative Revenues Under Collaboration Agreement Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block] Statement of Comprehensive Income [Abstract] Reclassification adjustments to net loss resulting from realized gains or losses on sale of securities Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax Other comprehensive income, tax Other Comprehensive Income (Loss), Tax Investment [Table] Investment [Table] Silicon Valley Bank Term Loan and Line of Credit [Member] Silicon Valley Bank Loan And Security Agreement [Member] Silicon Valley Bank Loan And Security Agreement [Member] Investment [Axis] Investment [Axis] Investment [Domain] Investment [Domain] Akarna Therapeutics, Ltd. [Member] Akarna Therapeutics, Ltd. [Member] Akarna Therapeutics, Ltd. [Member] Investment [Line Items] Investment [Line Items] Gain (loss) on sale of available-for-sale securities Available-for-sale Securities, Gross Realized Gain (Loss) Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Other-than-temporary impairment charges on available-for-sale securities Other than Temporary Impairment Losses, Investments, Available-for-sale Securities Collateral balance Compensating Balance, Amount Realized gain on sale of cost method investment Cost-method Investments, Realized Gain (Loss) Cost method investment ownership percentage Cost Method Investment, Ownership Percentage Cost Method Investment, Ownership Percentage Commitments Commitments and Contingencies Disclosure [Text Block] Valuation and Qualifying Accounts Disclosure [Table] Valuation and Qualifying Accounts Disclosure [Table] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves Type [Axis] Valuation Allowances and Reserves [Domain] Valuation Allowances and Reserves [Domain] Chargebacks and Prompt Payment [Member] Chargebacks and Prompt Payment [Member] Chargebacks and Prompt Payment [Member] Other Discounts [Member] Other Discounts [Member] Other Discounts [Member] Rebates [Member] Rebates [Member] Rebates [Member] Returns [Member] Sales Returns and Allowances [Member] Valuation and Qualifying Accounts Disclosure [Line Items] Valuation and Qualifying Accounts Disclosure [Line Items] Reserve Rollforward [Roll Forward] Reserve Rollforward [Roll Forward] Reserve Rollforward [Roll Forward] Discounts and Allowances Discounts and Allowances Discounts and Allowances Current period Provision for Doubtful Accounts Prior periods Allowance For Doubtful Accounts Receivable, Prior Period Adjustment Allowance For Doubtful Accounts Receivable, Prior Period Adjustment Payment and Credits Issued Payment and Credits Issued Payment and Credits Issued on Discounts and Allowances Discounts and Allowances Schedule of Fair Value of Financial Assets Measured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of Estimated Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Extinguishment of Debt [Table] Schedule of Extinguishment of Debt [Table] Silicon Valley Bank Loan And Security Agreement [Member] Extinguishment of Debt [Line Items] Extinguishment of Debt [Line Items] Term loan payable Induced Conversion of Convertible Debt Expense [Abstract] Induced Conversion of Convertible Debt Expense [Abstract] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Compensating balance Building [Member] Building [Member] Furniture and fixtures [Member] Equipment And Furniture [Member] Equipment And Furniture [Member]. Estimated useful lives Property, Plant and Equipment, Useful Life Summary of Cash Equivalents and Investments by Security Type Unrealized Gain (Loss) on Investments [Table Text Block] Fair Value and Gross Unrealized Losses on Investments Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block] Summary of Cash Equivalents and Investments by Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Maturing in one year or less Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Maturing after one year through five years Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Total Available-for-sale Securities, Debt Securities COTELLIC [Member] Cotellic [Member] Cotellic [Member] Royalty revenues on ex-U.S. sales of COTELLIC Royalty Revenue U.S. (loss) net cost recovery under the collaboration agreement included in Selling, general and administrative expenses Collaborative Arrangement, Income (Loss) from Agreement Collaborative Arrangement, Income (Loss) from Agreement Collaborative Arrangements with Glaxo Smith Kline [Member] Collaborative Arrangements with Glaxo Smith Kline [Member] Collaborative Arrangements with Glaxo Smith Kline Royalty expense Royalty Expense Aggregate principal amount of debt converted Redemption of convertible debt Debt Instrument, Redemption of Convertible Debt, Amount Debt Instrument, Redemption of Convertible Debt, Amount Inducements in conversion Induced Conversion of Convertible Debt Expense Cash inducements Repayments of interest required upon a conversion under the terms of the indenture that were not repaid under the terms of the exchange agreements Reduction of additional paid-in capital resulting from conversion Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement [Member] Portion at Fair Value Measurement [Member] Carrying Amount [Member] Reported Value Measurement [Member] Fair Value [Member] Estimate of Fair Value Measurement [Member] Fair value of financial instruments Long-term Debt, Fair Value Total revenues Gross profit Gross Profit Income (loss) from operations Operating Income (Loss) Organization And Summary Of Significant Policies [Table] Organization And Summary Of Significant Policies [Table] Organization And Summary Of Significant Policies [Table] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2016-09 [Member] Accounting Standards Update 2016-09 [Member] Products Derived from Cabozantinib [Member] Products Derived from Cabozantinib [Member] Products Derived from Cabozantinib [Member] Pro Forma [Member] Pro Forma [Member] Organization And Summary Of Significant Policies [Line Items] Organization And Summary Of Significant Policies [Line Items] Organization And Summary Of Significant Policies [Line Items] Number of products that entered in the commercial marketplace Number of Products in Commercial Market Number of Products in Commercial Market Number of reportable segments Number of Reportable Segments Impairment charge on goodwill Goodwill, Impairment Loss Percent discount for prompt payment Sales Revenue, Percent Discount for Prompt Payment Sales Revenue, Percent Discount for Prompt Payment Discount expected to be earned Sales Revenue, Discount Expected to be Earned, Percent Sales Revenue, Discount Expected to be Earned, Percent Adoption of Accounting Standards Update No. 2016-09 Net cash provided by operating activities Net cash used in financing activities Accumulated deficit Retained Earnings (Accumulated Deficit) Deferred tax assets: Deferred Tax Assets, Net [Abstract] Net operating loss carry-forwards Deferred Tax Assets, Operating Loss Carryforwards Book over tax depreciation and amortization Deferred Tax Assets, Property, Plant and Equipment Tax credit and charitable contribution carry-forwards Deferred Tax Assets, Tax Credit Carryforwards Deferred revenue Deferred Tax Assets, Deferred Income Amortization of deferred stock compensation – non-qualified Deferred Tax Assets Amortization Of Deferred Stock Compensation - Non-Qualified Deferred tax assets amortization of deferred stock compensation - non-qualified. Accruals and reserves not currently deductible Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves Other assets Deferred Tax Assets, Other Total deferred tax assets Deferred Tax Assets, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Net deferred tax assets Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Deferred Tax Liabilities, Net [Abstract] Unrealized gains on derivatives and other liabilities Deferred Tax Liabilities, Other Total deferred tax liabilities Deferred Tax Liabilities, Net Net deferred taxes Deferred Tax Assets, Net Quarterly Financial Data (Unaudited) Quarterly Financial Information [Text Block] Schedule of Allocated Employee Stock-Based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block] Schedule of Fair Value of Employee Share-Based Payments Awards Stock Option Assumptions and Weighted Average Fair Values Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Fair Value of Employee Share-Based Payments Awards ESPP Assumptions and Weighted Average Fair Values Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Summary of All Stock Option Activity Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of All RSU Activity Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Amortized Cost Available-for-sale Securities, Amortized Cost Basis Gross Unrealized Gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross Unrealized Losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Fair Value Available-for-sale Securities Investments Investment [Text Block] Income Taxes Income Tax Disclosure [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Short-term investments Short-term Investments Short-term restricted cash and investments Restricted Cash and Investments, Current Trade and other receivables, net Receivables, Net, Current Inventory, net Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Long-term investments Long-term Investments Long-term restricted cash and investments Restricted Cash and Investments, Noncurrent Property and equipment, net Goodwill Goodwill Other long-term assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation and benefits Accrued Employee Benefits, Current Accrued collaboration liabilities Accrued Collaboration Liability, Current Accrued Collaboration Liability, Current Rebates and fees due to customers Customer Refund Liability, Current Convertible notes Convertible Debt, Current Term loan payable Notes Payable, Current Other current liabilities Other Accrued Liabilities, Current Total current liabilities Liabilities, Current Other long-term liabilities Total liabilities Liabilities Commitments (Note 12) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued Preferred Stock, Value, Issued Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 296,209,426 and 289,923,798 at December 31, 2017 and 2016, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Liabilities and Equity Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Debt Schedule of Debt [Table Text Block] Summary of Loss on Extinguishment of Debt Schedule of Extinguishment of Debt [Table Text Block] RSUs [Member] Restricted Stock Units (RSUs) [Member] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Awards outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Awarded (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Vested and released (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Awards outstanding at end of period (in shares) Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Awards outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Awarded (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Vested and released (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Awards outstanding at end of period (in dollars per share) Weighted Average Remaining Contractual Term, Awards outstanding at December 31, 2017 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Aggregate Intrinsic Value, Awards outstanding at December 31, 2017 Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value. Milestones achieved Amortization of upfront payments and deferred milestone Recognition of Deferred Revenue Royalty revenue Development cost reimbursements Collaborative Arrangement, Development Cost Reimbursements Collaborative Arrangement, Development Revenue Product supply agreement revenue Sales Revenue, Goods, Net Cost of supplied product Cost of Goods Sold Royalty payable to GSK on net sales by Ipsen Collaboration revenues under the Ipsen Collaboration Agreement Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Income Tax Examination [Table] Income Tax Examination [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Federal [Member] Internal Revenue Service (IRS) [Member] State and Local Jurisdiction [Member] State and Local Jurisdiction [Member] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Research Tax Credit Carryforward [Member] Research Tax Credit Carryforward [Member] Income Tax Examination [Line Items] Income Tax Examination [Line Items] Tax Cuts and Jobs Act of 2017, reduction in deferred tax asset Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Gross Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Gross Tax Cuts and Jobs Act of 2017, change in valuation allowance Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Valuation Allowance Tax Cuts and Jobs Act of 2017, Change in Tax Rate, Effect On Deferred Tax Assets, Valuation Allowance Valuation allowance increase (decrease) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Net operating loss carryforwards Operating Loss Carryforwards Research and development tax credits Tax Credit Carryforward, Amount Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Income Statement [Abstract] Revenues: Revenues [Abstract] Net product revenues Total revenues Operating expenses: Operating Expenses [Abstract] Cost of goods sold Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Restructuring (recovery) charge Restructuring Charges Total operating expenses Operating Expenses Income (loss) from operations Other income (expense), net: Nonoperating Income (Expense) [Abstract] Interest income Interest Income, Other Interest expense Interest Expense Other, net Other Nonoperating Income (Expense) Total other expense, net Nonoperating Income (Expense) Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision for income taxes Net income (loss) Shares used in computing net income (loss) per share, basic (in shares) Shares used in computing net income (loss) per share, diluted (in shares) Schedule of Revenue by Major Customers, by Reporting Segments [Table] Schedule of Revenue by Major Customers, by Reporting Segments [Table] Cometriq [Member] Cometriq [Member] Cometriq [Member] Revenue, Major Customer [Line Items] Revenue, Major Customer [Line Items] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Common Stock and Warrants Stockholders' Equity Note Disclosure [Text Block] Schedule of Aggregate Future Minimum Lease Payments Under Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of Rent Expense Schedule of Rent Expense [Table Text Block] Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Inventory Inventory Disclosure [Text Block] U.S. federal income tax provision (benefit) at statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount State tax expense Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Debt extinguishment Effective Income Tax Rate Reconciliation, Extinguishment of Debt, Amount Effective Income Tax Rate Reconciliation, Extinguishment of Debt, Amount Non-deductible interest Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Stock-based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Performance Stock Options [Member] Performance Stock Options [Member] Performance Based Stock Options [Member] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Change in Control and Severance Benefit Plan [Member] Change in Control and Severance Benefit Plan [Member] Change in Control and Severance Benefit Plan [Member] Number of shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Stock options, vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Life of stock options granted Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Termination period prior to change in control Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Prior to Change in Control Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Prior to Change in Control Termination period subsequent to change in control Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Subsequent to Change in Control Share-based Compensation Arrangement by Share-based Payment Award, Termination Period Subsequent to Change in Control Extension of exercise period Share-based Compensation Arrangement by Share-based Payment Award, Exercise Period Extension Share-based Compensation Arrangement by Share-based Payment Award, Exercise Period Extension Discount rate from market value on purchase date (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date Discount rate from market value on offering date (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date Purchase period Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Offering Date, Purchase Period Stock-based compensation expense Common stock issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Average price per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Per Share Weighted Average Price of Shares Purchased Total unrecognized compensation expense Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation expense weighted-average period for recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Cash received from option exercises and purchases under the ESPP Fair value of employee options vested and expensed Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested And Expensed, Fair Value Share-based compensation arrangement by share-based payment award, options, vested and expensed, fair value. Number of options in vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Options outstanding (in shares) Retirement Plan, employee contribution (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate Employer matching contributions for first 3% of participant contributions (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Match Percentage of participant contributions into the 401(k) Retirement Plan (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Expenses relating to stock match Defined Contribution Plan, Cost Number of shares available for issuance under 401(k) Retirement Plan (in shares) Defined Contribution Plan, Number of Shares Available for Grant Defined Contribution Plan, Number of Shares Available for Grant Basis of Consolidation Consolidation, Policy [Policy Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Reclassifications Reclassification, Policy [Policy Text Block] Cash and Investments Cash and Cash Equivalents, Policy [Policy Text Block] Investments Marketable Securities, Policy [Policy Text Block] Accounts Receivable Trade and Other Accounts Receivable, Policy [Policy Text Block] Fair Value Measurements Fair Value of Financial Instruments, Policy [Policy Text Block] Inventory Inventory, Policy [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Revenue Recognition Revenue Recognition, Policy [Policy Text Block] Cost of Goods Sold Cost of Sales, Policy [Policy Text Block] Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Foreign Currency Translation and Remeasurement Foreign Currency Transactions and Translations Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Concentration Risk [Table] Concentration Risk [Table] Diplomat Specialty Pharmacy [Member] Diplomat Specialty Pharmacy [Member] Diplomat Specialty Pharmacy Caremark L.L.C. [Member] Caremark L.L.C. [Member] Caremark L.L.C. [Member] Ipsen [Member] Ipsen [Member] Ipsen [Member] Accredo Health, Incorporated [Member] Accredo Health, Incorporated [Member] Accredo Health, Incorporated [Member] Affiliates of McKesson Corporation [Member] Affiliates of McKesson Corporation [Member] Affiliates of McKesson Corporation [Member] Customer concentration risk [Member] Customer Concentration Risk [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk Concentration Risk, Percentage Capital lease and other financing lease [Member] Capital Lease and Other Financing Lease [Member] Capital Lease and Other Financing Lease [Member] Depreciation Depreciation Tenant improvements allowance Tenant Lease Improvements, Allowance Tenant Lease Improvements, Allowance Construction in process costs capitalized Property, Plant and Equipment, Additions Prepaid construction costs Prepaid Expense Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Bristol Myers Squibb [Member] Bristol Myers Squibb [Member] Bristol-Myers Squibb [Member]. Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member] Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] [Member] Collaborative Arrangement with Two Bristol-Myers Squibb Compound Utilized [Member] Daiichi Sankyo [Member] Collaborative Arrangement with Daiichi Sankyo [Member] Collaborative Arrangement with Daiichi Sankyo [Member] Merck [Member] Collaborative Arrangement with Merck [Member] Collaborative Arrangement with Merck [Member] Collaborative Arrangement with BMS [Member] Collaborative Arrangement with BMS [Member] Collaborative Arrangement with BMS [Member] Sanofi [Member] Sanofi Aventis [Member] Sanofi - Aventis [Member]. Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Percentage of maximum potential milestone payments - clinical development Percentage of Maximum Potential Milestone Payments - Clinical Development Percentage of Maximum Potential Milestone Payments - Clinical Development Percentage of maximum potential milestone payments - regulatory Percentage of Maximum Potential Milestone Payments - Regulatory Percentage of Maximum Potential Milestone Payments - Regulatory Percentage of maximum potential milestone payments - commercial Percentage of Maximum Potential Milestone Payments - Commercial Percentage of Maximum Potential Milestone Payments - Commercial Percentage of costs Collaborative Arrangement, Share in Costs, Percentage Collaborative Arrangement, Share in Costs, Percentage Maximum amount eligible for royalties on sales under collaborations agreement Maximum Amount Eligible For Royalties on Sales Under Collaborations Agreement Maximum Amount Eligible For Royalties on Sales Under Collaborations Agreement Percent of royalty on net sales